Novartis Appoints AbbVie Immunology Leader Horber To Succeed Tschudin
President of Innovative Medicines International and chief commercial officer Marie-France Tschudin will leave Novartis after nearly seven years.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.
US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.